<DOC>
	<DOC>NCT01839630</DOC>
	<brief_summary>This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course (concomitantly use no later than the 3rd TACE procedure) has been made under real-life practice conditions.this study will also conclude the safety and effectiveness of combination in uHCC patients.</brief_summary>
	<brief_title>Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients with histologically/ cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multidimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI; Patients receive the first dose of sorafenib no later than 1 week (&lt;=7days) after the 3rd TACE procedure Patients did not receive other prior systemic treatment by using target therapy Patients must sign the informed consent form; Patients must have a life expectancy of at least 3 months; The physician must be willing to complete and submit all CRFs; The physician must be willing to submit to a site audit with verification of source documents and validation of data reported; The first dose of sorafenib 7 days after the 3nd TACE procedure Exclusion criteria must follow the approved local product information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Hepatocellular cancer</keyword>
	<keyword>TACE combination</keyword>
	<keyword>Treatment pattern</keyword>
	<keyword>Safety</keyword>
	<keyword>Effectiveness</keyword>
</DOC>